FAILED TRIAL: FIRST trial of Jemperli (dostarlimab) + chemo and Zejula maintenance +/- avastin met primary endpoint of PFS but not OS in 1L advanced ovarian cancer December 25, 2024
Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer Announced December 25, 2024
Continued Strong Improvement in OS Data from Ph 2 OVATION 2 Study of IMNN-001 Announced December 18, 2024
Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Ph 1 Gynecologic Expansion Clinical Trial Announced December 18, 2024
FAILED TRIAL: Ph 3 KEYLYNK-001 Trial Met Primary Endpoint of PFS, but not OS, in Patients With Advanced Epithelial Ovarian Cancer December 10, 2024
Results from End-of-Phase 2 Meeting with FDA for IMNN-001 Program in Advanced Ovarian Cancer Announced November 26, 2024
European Commission Approves ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer November 19, 2024
Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer Completed November 5, 2024
First Patient Dosed in Ph 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers November 5, 2024
IGCS 2024: Positive Updated RAMP 201 Data for Avutometinib & Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer Presented October 22, 2024
First Patient Dosed in Ph 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients October 15, 2024
Cartherics raises over $15 Million in oversubscribed private financing round to advance cell therapy programs October 8, 2024
Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer September 24, 2024
Two Patients Now Exceeding 1 Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial September 22, 2024
Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers September 3, 2024
11.1 Month Increase in OS in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001 in OVATION 2 Ph 2 trial Announced August 6, 2024
Database Lock announced for Ph 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer July 1, 2024
Stenoparib Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer in Ph 2 clinical trial July 1, 2024
